Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study

Tuberculosis

Volumn 100, Issue , 2016, Pages 118-127

  Gillard, Paul ^a   Yang, Pan Chyr ^b   Danilovits, Manfred ^c   Su, Wei Juin ^d   Cheng, Shih Lung ^e   Pehme, Lea ^c   Bollaerts, Anne ^a   Jongert, Erik ^a   Moris, Philippe ^a   Ofori Anyinam, Opokua ^a   Demoitié, Marie Ange ^a   Castro, Marcela ^a  

^a GSK   (Belgium)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c TARTU UNIVERSITY HOSPITAL   (Estonia)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Immunogenicity; M72 AS01E vaccine; Safety; T cell; Tuberculosis

Indexed keywords

AMINOTRANSFERASE; BCG VACCINE; BILIRUBIN; CD40 LIGAND; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; M72 AS01E VACCINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY;

ADULT; ADULT DISEASE; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BCG VACCINATION; BILIRUBIN BLOOD LEVEL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FLOW CYTOMETRY; FOLLOW UP; HEADACHE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; INJECTION SITE REACTION; INJECTION SITE REDNESS; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; TUBERCULOSIS; ADOLESCENT; BIOSYNTHESIS; CELLULAR IMMUNITY; CLINICAL TRIAL; ERYTHEMA; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; CD4-POSITIVE T-LYMPHOCYTES; ERYTHEMA; FEMALE; HUMANS; IMMUNITY, CELLULAR; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PAIN; SINGLE-BLIND METHOD; TUBERCULOSIS; TUBERCULOSIS VACCINES; YOUNG ADULT;

EID: 84982095386     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2016.07.005     Document Type: Article

References (47)

1. [1] World Health Organization, Global tuberculosis report., 2015 Geneva, Switzerland. Report No.: WHO/HTM/TB/2015.22.
2. [2] Hur, Y.G., Gorak-Stolinska, P., Ben-Smith, A., Lalor, M.K., Chaguluka, S., Dacombe, R., Doherty, T.M., Ottenhoff, T.H., Dockrell, H.M., Crampin, A.C., Combination of cytokine responses indicative of latent TB and active TB in Malawian adults. PLoS One, 8, 2013, e79742, 10.1371/journal.pone.0079742.
3. [3] Druszczynska, M., Wlodarczyk, M., Janiszewska-Drobinska, B., Kielnierowski, G., Zawadzka, J., Kowalewicz-Kulbat, M., Fol, M., Szpakowski, P., Rudnicka, K., Chmiela, M., Rudnicka, W., Monocyte signal transduction receptors in active and latent tuberculosis. Clin Dev Immunol, 2013, 851452, 10.1155/2013/851452.
4. [4] Kunnath-Velayudhan, S., Gennaro, M.L., Immunodiagnosis of tuberculosis: a dynamic view of biomarker discovery. Clin Microbiol Rev 24 (2011), 792–805, 10.1128/cmr.00014-11.
5. [5] Rakotosamimanana, N., Doherty, T.M., Andriamihantasoa, L.H., Richard, V., Gicquel, B., Soares, J.L., Zumla, A., Razanamparany, V.R., Expression of TNF-alpha-dependent apoptosis-related genes in the peripheral blood of Malagasy subjects with tuberculosis. PLoS One, 8, 2013, e61154, 10.1371/journal.pone.0061154.
6. [6] Barry, C.E. 3rd, Boshoff, H.I., Dartois, V., Dick, T., Ehrt, S., Flynn, J., Schnappinger, D., Wilkinson, R.J., Young, D., The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7 (2009), 845–855, 10.1038/nrmicro2236.
7. [7] Mangtani, P., Abubakar, I., Ariti, C., Beynon, R., Pimpin, L., Fine, P.E., Rodrigues, L.C., Smith, P.G., Lipman, M., Whiting, P.F., Sterne, J.A., Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 58 (2014), 470–480, 10.1093/cid/cit790.
8. [8] Ottenhoff, T.H., Kaufmann, S.H., Vaccines against tuberculosis: where are we and where do we need to go?. PLoS Pathog, 8, 2012, e1002607, 10.1371/journal.ppat.1002607.
9. [9] da Costa, C., Walker, B., Bonavia, A., Tuberculosis vaccines–state of the art, and novel approaches to vaccine development. Int J Infect Dis 32 (2015), 5–12, 10.1016/j.ijid.2014.11.026.
10. [10] Montoya, J., Solon, J.A., Cunanan, S.R., Acosta, L., Bollaerts, A., Moris, P., Janssens, M., Jongert, E., Demoitie, M.A., Mettens, P., Gatchalian, S., Vinals, C., Cohen, J., Ofori-Anyinam, O., A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults. J Clin Immunol 33 (2013), 1360–1375, 10.1007/s10875-013-9949-3.
11. [11] Leroux-Roels, I., Forgus, S., De Boever, F., Clement, F., Demoitié, M.A., Mettens, P., Moris, P., Ledent, E., Leroux-Roels, G., Ofori-Anyinam, O., M72 Study Group. Improved CD4(+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 31 (2013), 2196–2206, 10.1016/j.vaccine.2012.05.035.
12. [12] Day, C.L., Tameris, M., Mansoor, N., van Rooyen, M., de Kock, M., Geldenhuys, H., Erasmus, M., Makhethe, L., Hughes, E.J., Gelderbloem, S., Bollaerts, A., Bourguignon, P., Cohen, J., Demoitie, M.A., Mettens, P., Moris, P., Sadoff, J.C., Hawkridge, A., Hussey, G.D., Mahomed, H., Ofori-Anyinam, O., Hanekom, W.A., Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. Am J Respir Crit Care Med 188 (2013), 492–502, 10.1164/rccm.201208-1385OC.
13. [13] Penn-Nicholson, A., Geldenhuys, H., Burny, W., van der Most, R., Day, C.L., Jongert, E., Moris, P., Hatherill, M., Ofori-Anyinam, O., Hanekom, W.Vaccine Study Team, Bollaerts, A., Demoitie, M.A., Kany Luabeya, A.K., De Ruymaeker, E., Tameris, M., Lapierre, D., Scriba, T.J., Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting. Vaccine 33 (2015), 4025–4034, 10.1016/j.vaccine.2015.05.088.
14. [14] Thacher, E.G., Cavassini, M., Audran, R., Thierry, A.C., Bollaerts, A., Cohen, J., Demoitie, M.A., Ejigu, D., Mettens, P., Moris, P., Ofori-Anyinam, O., Spertini, F., Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial. AIDS 28 (2014), 1769–1781, 10.1097/QAD.0000000000000343.
15. [15] Idoko, O.T., Owolabi, O.A., Owiafe, P.K., Moris, P., Odutola, A., Bollaerts, A., Ogundare, E., Jongert, E., Demoitié, M.A., Ofori-Anyinam, O., Ota, M.O., Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial. Tuberc (Edinb) 94 (2014), 564–578, 10.1016/j.tube.2014.07.001.
16. [16] Verver, S., Warren, R.M., Beyers, N., Richardson, M., van der Spuy, G.D., Borgdorff, M.W., Enarson, D.A., Behr, M.A., van Helden, P.D., Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 171 (2005), 1430–1435, 10.1164/rccm.200409-1200OC.
17. [17] Habermehl, P., Leroux-Roels, G., Sanger, R., Machler, G., Boutriau, D., Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2, 3, 4 months schedule with a fourth dose at 12-18 months of age. Hum Vaccin, 6, 2010 doi: 12154 [pii].
18. [18] U.S. Department of Health and Human Services - Food and Drug Administration, Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. September 2007.
19. [19] Moris, P., van der Most, R., Leroux-Roels, I., Clement, F., Drame, M., Hanon, E., Leroux-Roels, G.G., Van Mechelen, M., H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 31 (2011), 443–454, 10.1007/s10875-010-9490-6.
20. [20] Didierlaurent, A.M., Collignon, C., Bourguignon, P., Wouters, S., Fierens, K., Fochesato, M., Dendouga, N., Langlet, C., Malissen, B., Lambrecht, B.N., Garçon, N., Van Mechelen, M., Morel, S., Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol 193 (2014), 1920–1930, 10.4049/jimmunol.1400948.
21. [21] Lal, H., Cunningham, A.L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.J., Levin, M.J., McElhaney, J.E., Poder, A., Puig-Barbera, J., Vesikari, T., Watanabe, D., Weckx, L., Zahaf, T., Heineman, T.C., ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372 (2015), 2087–2096, 10.1056/NEJMoa1501184.
22. [22] The RTS SCTP, Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386 (2015), 31–45, 10.1016/S0140-6736(15)60721-8.
23. [23] Nathan, C., Points of control in inflammation. Nature 420 (2002), 846–852, 10.1038/nature01320.
24. [24] Vandepapeliere, P., Horsmans, Y., Moris, P., Van Mechelen, M., Janssens, M., Koutsoukos, M., Van Belle, P., Clement, F., Hanon, E., Wettendorff, M., Garçon, N., Leroux-Roels, G., Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26 (2008), 1375–1386, 10.1016/j.vaccine.2007.12.038.
25. [25] Cohen, J.I., Hohman, P., Fulton, R., Turk, S.P., Qin, J., Thatcher, K., Hornung, R.L., Kinetics of serum cytokines after primary or repeat vaccination with the smallpox vaccine. J Infect Dis 201 (2010), 1183–1191, 10.1086/651453.
26. [26] Satti, I., Meyer, J., Harris, S.A., Manjaly Thomas, Z.R., Griffiths, K., Antrobus, R.D., Rowland, R., Ramon, R.L., Smith, M., Sheehan, S., Bettinson, H., McShane, H., Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. Lancet Infect Dis 14 (2014), 939–946, 10.1016/S1473-3099(14)70845-X.
27. [27] Sheehan, S., Harris, S.A., Satti, I., Hokey, D.A., Dheenadhayalan, V., Stockdale, L., Manjaly Thomas, Z.R., Minhinnick, A., Wilkie, M., Vermaak, S., Meyer, J., O'Shea, M.K., Pau, M.G., Versteege, I., Douoguih, M., Hendriks, J., Sadoff, J., Landry, B., Moss, P., McShane, H., A phase I, open-label trial, evaluating the safety and immunogenicity of candidate tuberculosis vaccines AERAS-402 and MVA85A, administered by prime-boost regime in BCG-vaccinated healthy adults. PLoS One, 10, 2015, e0141687, 10.1371/journal.pone.0141687.
28. [28] Ndiaye, B.P., Thienemann, F., Ota, M., Landry, B.S., Camara, M., Dieye, S., Dieye, T.N., Esmail, H., Goliath, R., Huygen, K., January, V., Ndiaye, I., Oni, T., Raine, M., Romano, M., Satti, I., Sutton, S., Thiam, A., Wilkinson, K.A., Mboup, S., Wilkinson, R.J., McShane, H., MVA85A 030 Trial Investigators. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 3 (2015), 190–200, 10.1016/S2213-2600(15)00037-5.
29. [29] Vilaplana, C., Montané, E., Pinto, S., Barriocanal, A.M., Domenech, G., Torres, F., Cardona, P.J., Costa, J., Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. Vaccine 28 (2010), 1106–1116, 10.1016/j.vaccine.2009.09.134.
30. + T cells in adults. Am J Respir Crit Care Med 181 (2010), 1407–1417, 10.1164/rccm.200910-1484OC.
31. [31] Hoft, D.F., Blazevic, A., Stanley, J., Landry, B., Sizemore, D., Kpamegan, E., Gearhart, J., Scott, A., Kik, S., Pau, M.G., Goudsmit, J., McClain, J.B., Sadoff, J., A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. Vaccine 30 (2012), 2098–2108, 10.1016/j.vaccine.2012.01.048.
32. [32] Dheda, K., Booth, H., Huggett, J.F., Johnson, M.A., Zumla, A., Rook, G.A., Lung remodeling in pulmonary tuberculosis. J Infect Dis 192 (2005), 1201–1209, 10.1086/444545.
33. [33] Rook, G.A., al Attiyah, R., Cytokines and the Koch phenomenon. Tubercle 72 (1991), 13–20.
34. [34] Cardona, P.J., Llatjós, R., Gordillo, S., Díaz, J., Viñado, B., Ariza, A., Ausina, V., Towards a ‘human-like’ model of tuberculosis: intranasal inoculation of LPS induces intragranulomatous lung necrosis in mice infected aerogenically with Mycobacterium tuberculosis. Scand J Immunol 53 (2001), 65–71, 10.1046/j.1365-3083.2001.00842.x.
35. [35] Roach, T.I., Barton, C.H., Chatterjee, D., Blackwell, J.M., Macrophage activation: lipoarabinomannan from avirulent and virulent strains of Mycobacterium tuberculosis differentially induces the early genes c-fos, KC, JE, and tumor necrosis factor-alpha. J Immunol 150 (1993), 1886–1896.
36. [36] Bansal, R., Sharma, P.K., Exaggerated Mantoux reaction in a case of latent tuberculosis infection (LTBI). Indian J Tuberc 59 (2012), 171–173.
37. [37] Avasthi, R., Chaudhary, S.C., Mohanty, D., Giant Mantoux reaction. Indian J Med Microbiol 27 (2009), 78–79.
38. [38] Bristowe, J.S., An address on the Koch method of treatment for tuberculosis. Br Med J 1 (1891), 893–896.
39. [39] Moreira, A.L., Tsenova, L., Aman, M.H., Bekker, L.G., Freeman, S., Mangaliso, B., Schroder, U., Jagirdar, J., Rom, W.N., Tovey, M.G., Freedman, V.H., Kaplan, G., Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice. Infect Immun 70 (2002), 2100–2107.
40. [40] Roestenberg, M., Remarque, E., de Jonge, E., Hermsen, R., Blythman, H., Leroy, O., Imoukhuede, E., Jepsen, S., Ofori-Anyinam, O., Faber, B., Kocken, C.H., Arnold, M., Walraven, V., Teelen, K., Roeffen, W., de Mast, Q., Ballou, W.R., Cohen, J., Dubois, M.C., Ascarateil, S., van der Ven, A., Thomas, A., Sauerwein, R., Safety and immunogenicity of a recombinant plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel™, montanide ISA 720 or AS02. PLoS One, 3, 2008, e3960.
41. [41] Thera, M.A., Doumbo, O.K., Coulibaly, D., Laurens, M.B., Kone, A.K., Guindo, A.B., Traore, K., Sissoko, M., Diallo, D.A., Diarra, I., Kouriba, B., Daou, M., Dolo, A., Baby, M., Sissoko, M.S., Sagara, I., Niangaly, A., Traore, I., Olotu, A., Godeaux, O., Leach, A., Dubois, M.C., Ballou, W.R., Cohen, J., Thompson, D., Dube, T., Soisson, L., Diggs, C.L., Takala, S.L., Lyke, K.E., House, B., Lanar, D.E., Dutta, S., Heppner, D.G., Plowe, C.V., Safety and immunogenicity of an AMA1 malaria vaccine in malian children: results of a phase 1 randomized controlled trial. PLoS One, 5, 2010, e9041.
42. [42] Spertini, F., Audran, R., Lurati, F., Ofori-Anyinam, O., Zysset, F., Vandepapeliere, P., Moris, P., Demoitie, M.A., Mettens, P., Vinals, C., Vastiau, I., Jongert, E., Cohen, J., Ballou, W.R., The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study. Tuberc (Edinb) 93 (2013), 179–188, 10.1016/j.tube.2012.10.011.
43. [43] Flynn, J.L., Chan, J., Triebold, K.J., Dalton, D.K., Stewart, T.A., Bloom, B.R., An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178 (1993), 2249–2254.
44. + T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8 (2007), 369–377, 10.1038/ni1449.
45. [45] Millington, K.A., Innes, J.A., Hackforth, S., Hinks, T.S., Deeks, J.J., Dosanjh, D.P., Guyot-Revol, V., Gunatheesan, R., Klenerman, P., Lalvani, A., Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J Immunol 178 (2007), 5217–5226, 10.4049/jimmunol.178.8.5217.
46. [46] Roach, D.R., Bean, A.G., Demangel, C., France, M.P., Briscoe, H., Britton, W.J., TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168 (2002), 4620–4627.
47. [47] Forbes, E.K., Sander, C., Ronan, E.O., McShane, H., Hill, A.V., Beverley, P.C., Tchilian, E.Z., Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 181 (2008), 4955–4964.